Kornimate/medical-research-clean huggingface dataset:
effect of exercise on appetite in response to meals

Conditions: Healthy

Summary: this clinical trial's primary aim is to investigate the acute effect of two exercise bouts (short \[10 minutes\] and long \[30 minutes\]) on appetite and appetite-regulatory hormone responses to a standard meal test. the secondary aim is to investigate when the changes in appetite and appetite-regulatory hormones occur during exercise. as an exploratory aim, the researchers will test if the two exercise bouts influence ad libitum energy intake in the periods after the standard meal test. the researchers will compare three groups (control, short exercise, and prolonged exercise) to see if the exercise bouts affect appetite, appetite-regulatory hormones, and energy intake in healthy men.

study design screening visit before conducting the main experiments, the participants will attend a screening visit where consent will be obtained, and they will complete questionnaires to assess health, food preferences, and physical activity. the researchers will then measure the participants' height, weight, waist circumference, and body composition. after the researchers confirm the eligibility criteria, participants will take part in two treadmill tests to establish maximum oxygen uptake test (v̇o2 max) (broom et al. 2017). experimental design after the screening visit, the participants will complete three main experiments (control, short high-intensity exercise, and prolonged high-intensity exercise) in a counter-balanced design. all experiments began at \~0930, following an overnight fast of at least 10 hours. participants will consume a prescribed meal in the evening before each main experiment. following this meal, participants are only allowed to drink water until the start of the main experiments. at the beginning of the exercise conditions, participants will run on the treadmill for 10 minutes (short) or 30 minutes (prolonged) at a speed estimated to elicit a 75% v̇o2 peak, followed by rest in the laboratory. in the control condition, the researchers will follow the same protocols except that the participants will not perform any exercise. the participants will have a standardized meal after exercise and then an ad libitum buffet meal afterward. during each experiment, the researchers will assess appetite ratings using 100 mm visual analog scales (flint et al. 2000). the researchers will also collect blood samples to examine ghrelin, peptide yy, glucagon-like peptide 1, and possibly other blood-borne measures.

Eligibility criteria:
inclusion criteria: * males aged 18 years or older. * have stable body mass for at least six months (within ±2 kg). exclusion criteria: * females * people who are younger than 18 or older than 65 years old. * have food allergies. * have significant contraindications to exercise (e.g., an injury that would inhibit running). * smoking. * suffering from metabolic health issues, e.g., history of diabetes, cardiovascular disease, or eating disorders.
exploring merkel cell carcinoma clinical trial engagement patterns

Conditions: Merkel Cell Carcinoma

Summary: taking part in medical research usually favors a particular demographic group. but there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. this study will admit a wide range of data on the clinical trial experience of merkel cell carcinoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. it will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future merkel cell carcinoma patients.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * able to comprehend the investigational nature of the protocol and provide informed consent * diagnosis of merkel cell carcinoma exclusion criteria: * no diagnosis of merkel cell carcinoma confirmed * inability to perform regular electronic reporting * patient does not understand, sign, and return consent form

Keywords: merkel cell carcinoma
effects of lutein supplementation on subclinical atherosclerosis

Conditions: Carotid Atherosclerosis; Carotid Intimal Medial Thickness 1

Summary: this study is to investigate the possible positive effects of lutein and lycopene supplementation on early atherosclerosis in beijing.

atherosclerosis is the primary cause of cardiovascular and cerebrovascular diseases, both of which are the top two causes of death in industrialized countries including china. lutein was found to be protective against atherosclerosis in some case control studies. however, the intervention on atherosclerosis have not been reported. in the present study, 192 subjects were randomly assigned to four groups treated with different amounts of lutein. the investigators observe the changes of serum lutein concentration by hyper-pressure liquid chromatography (hplc), and compare the differences of common carotid imt and arterial stiffness by carotid ultrasonography before and after the intervention. serum biochemistry indexes including cholesterol (cho), triglyceride (tg), high density lipoprotein-cholesterol (hdl-c), low density lipoprotein-cholesterol (ldl-c) and glucose (glu) were measured at 0, 7 and 12 months of treatment by auto-analyzer.

Eligibility criteria:
inclusion criteria: * early atherosclerosis; * aged 45 to 68 years; * han nationality exclusion criteria: * history of myocardial infarction, * stroke, * revascularization, * coronary by-pass operation, * local carotid imt \> 1300μm or supplemental vitamin and/or mineral use for ≥ 4 week before the start of the study

Keywords: early atherosclerosis serum lutein serum lycopene intima-media thickness arterial stiffness combined effect
an observational, prospective, safety study of mircera (monopegylated epoetin beta) in clinical practice

Conditions: Kidney Disease, Chronic

Summary: this national study was a post-marketing surveillance study conducted in korea from 29 august 2008 to 28 august 2012 to meet local regulatory requirements for mircera (monopegylated-epoetin beta). prospective participant-based data collection was evaluated for safety/risk assessments and effectiveness. no specific study-related procedures are required. participants were to be followed up as long as possible at the physician's discretion.


Eligibility criteria:
inclusion criteria: * adult, aged \>18 years * participants with stage 3-5 chronic kidney disease and hemodialyzed participants * signed informed consent exclusion criteria: * current participation in a clinical study
comparing the effect of toe-in gait modification along with conventional physiotherapy in people with medial ko

Conditions: Knee Osteoarthritis

Summary: medial knee osteoarthritis (oa) remains a prevalent and debilitating condition, despite conventional physiotherapy interventions aimed at reducing pain and improving function. this study investigates the additional benefits of toe-in gait modification when combined with conventional physiotherapy in individuals with medial knee oa. rooted in biomechanical theories suggesting that altering gait patterns can reduce medial knee load, this research employs a randomized controlled trial methodology.

participants are divided into two groups: one receiving conventional physiotherapy alone, and the other receiving a combination of conventional physiotherapy and toe-in gait modification. outcomes are assessed over a 8-week period, focusing on pain levels and physical function. the significance of this study lies in its potential to enhance current treatment protocols, offering a more effective, non-invasive intervention to alleviate symptoms and improve the quality of life for those suffering from medial knee oa. the findings could inform clinical practices and pave the way for personalized rehabilitation strategies that incorporate gait modifications, ultimately reducing the healthcare burden associated with knee osteoarthritis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mkoa having grade 1-3 (radiographic evidence of mkoa) * knee pain on most days of previous month. (the most symptomatic side will consider the study limb for participants with bilaterally eligible knees) * age \> 45 * ability to walk unaided for at least 25 min * gender eligibility both male and female exclusion criteria: * severe mkoa (grade 4) * lateral oa * patella femoral oa * previous or planned hip or knee surgery * hip or ankle arthritis * rheumatoid arthritis * severe valgus and varus alignment requiring the use of an assistive device and the inability to walk independently * neurological dysfunction
predictors of node positivity in endometrial cancer

Conditions: Endometrial Cancer

Summary: to investigate the role of histological and moleculr profile of endometrial cancer patietns in predicting the risk of nodal metastases in endometrila cancer patients.


Eligibility criteria:
inclusion criteria: * written informed consent * histologically confirmed endometrila cancer * data on molecular genomic profiling (pole mutated, p53 abnormalities, mmrd/msi-h, and nsmp) * data on histological characteristics of the ttumor * execution of sentinel node mapping * data on sentinel node status (negative vs. positive) exclusion criteria: * stage ivb endoemtrial cancer * consent withdraw

Keywords: sentinel node endometrial cancer
computer-aided detection during screening colonoscopy (experts)

Conditions: Colorectal Neoplasms; Colon Polyp; Colon Adenoma

Summary: evaluation of the colonic mucosa with a high definition colonoscope (epki7010 video processor). the endoscopy images will be seen on a 27inch, flat-panel, high-definition lcd monitor (radiance™ ultrasc-wu27-g1520 model) only by one expert endoscopist, randomly assigned. the number, location, and polyps' features (paris classification) will be recorded by the operator. if a polyp is detected, the endoscopist will remove the polyp endoscopically with a cold snare. the same patient will be submitted to a second, the same session, computed aided real-time colonoscopy using the discovery, ai-assisted polyp detector. colonoscopy will be performed by a same-level-of-expertise operator in comparison to the initial procedure. any polyp or lesion detected with the ai system will be recorded and endoscopically removed and considered as a missed lesion from standard colonoscopy.

screening colonoscopy has decreased the incidence of colorectal carcinoma in the previous decades. however, there are reports of missed polyps and interval crc following screening colonoscopy. several factors may affect the adr, pdr, and missed lesions rates, such as bowel preparation, percentage of mucosal surface evaluation, and the training levels of operators. artificial intelligence using deep-learning algorithms has been implemented in gastrointestinal endoscopy, mainly for the detection and diagnosis of gi tract lesions such as colonic polyps and adenomas. the implementation of automated polyp detection software during screening colonoscopy may prevent the missing of polyp and adenoma during screening colonoscopy. therefore, improving the adr and pdr during colonoscopies. all of this, with the aim of decrease the incidence of interval colorectal carcinoma (crc), and crc-related morbidity and mortality. the discovery artificial intelligence assisted polyp detector (pentax medical, hoya group) was recently launched for clinical practice. this ai software was trained with 120,000 files from approximately 300 clinical cases. the visual aided detection (bounding box locating a polyp on the monitor) will alert the endoscopist if a polyp/adenoma was missed during the standard, screening procedure. to the best of our knowledge, this may be the first study evaluating the discovery ai-assisted polyp detector on clinical practice in the western hemisphere. the investigators aim to evaluate the real-world effectiveness of ai-assisted colonoscopy in clinical practice. the investigators will also evaluate the role of endoscopists' levels of training in the adr, pdr, and missed lesion rate.

Eligibility criteria:
inclusion criteria: * provided informed written consent * age greater than 45 years of age * adequate bowel preparation exclusion criteria: * history of inflammatory bowel disease, familial polyposis syndrome * history of colorectal carcinoma, colorectal surgery * history of uncontrolled coagulopathy * history of previously failed attempt colonoscopy

Keywords: colonoscopy colorectal cancer
proalgazyme novel algae infusion: applications in metabolic syndrome

Conditions: Metabolic Syndrome X

Summary: the purpose of this study is to compare the effects of supplementation with proalgazyme (a novel fermentation product of a freshwater algae ecosystem) vs. placebo on metabolic syndrome and indicators of cardiovascular health including: body weight and fat, blood lipids, inflammatory markers such as hscrp, blood pressure and fasting blood glucose.

metabolic syndrome, a set of symptoms strongly associated with increased risk for both cardiovascular disease and diabetes, is generally linked to obesity and has become a serious problem in many industrialized countries. agents that aid in weight loss or help to normalize blood lipids or inflammation may reduce the risk of metabolic syndrome and therefore, reduce the risk of cardiovascular disease and diabetes. this study is a single-center, double-blind, placebo-controlled, parallel design, to evaluate the effects of proalgazyme (4 fl. oz. daily) on metabolic syndrome and markers of cardiovascular health including blood lipids, inflammatory markers and anthropometric measurements. comparisons: proalgazyme vs. placebo \[time frame: 10 weeks\]

Eligibility criteria:
inclusion criteria: * participants must meet 3 of the following criteria: * bmi ≥30 kg/m2 * hdl cholesterol of \<40 * triglycerides \>150 mg/dl * fasting blood glucose \>100 mg/dl * blood pressure \>130/85 mm hg * total cholesterol of \>200 mg/dl * ldl cholesterol of \>160 mg/dl * interleukin 6 (il-6) \>5pg/ml exclusion criteria: * morbidly obese: bmi \>40 kg/m2 * taking any cholesterol-lowering medications 30 days prior to the start of enrollment and during the course of the study. * enrolled in another clinical study in the past 6 months. * pregnant, actively infected, on medication that interfered with healing (for example, steroids), were inflicted with systemic disease such as aids, hiv, active hepatitis or active malignancy (clinical signs within the past 5 years), or suffered from diabetes mellitus requiring daily insulin management.

Keywords: proalgazyme metabolic syndrome inflammation cardiovascular hscrp lipids algae
an extended access program for perampanel

Conditions: Partial Onset Seizures

Summary: the extended access program (eap) is a managed access programme for perampanel. the main objective of this eap is to ensure that patients participating in studies e2007-a001-207, e2007-g000-307, or e2007-g000-235 continue to have access to perampanel until such time perampanel tablets become commercially available for the treatment of partial onset seizures (pos) in the country in which they reside. this eap will consist of 2 phases: * screening: the patient will start the program once the screening assessments are completed and the patient is qualified for participation. * treatment: additional assessments, physical examinations, and dosage changes will be clinically determined by the treating physician. patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in previous study. doses of perampanel and of concomitant anti-epileptic drugs (aeds) can be adjusted (i.e., added,removed, or changed in dose) based on clinical judgment. treatment will be prescribed as long as clinically appropriate according to the judgement of the treating physician and the approved summary of product characteristics (smpc). the program will complete in a staggered fashion, country by country, as and when perampanel becomes commercially available for the treatment of pos in each country.


Eligibility criteria:
inclusion criteria: * patients who are participating in either study 207, study 307, or study 235 and who in the opinion of the treating physician, continue to benefit from treatment with perampanel (revised per amendment 01) * patients who provide informed consent where applicable per local requirements. * female patients of childbearing potential must agree for the duration of the program and for a period of at least 1 month following last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (e.g., a double-barrier method \[condom plus spermicide, condom plus diaphragm with spermicide\]) exclusion criteria: * patients residing in countries where perampanel is commercially available for the treatment of pos * female patients who are lactating, pregnant, or planning to become pregnant

Keywords: anti-epileptic drug extended access program partial onset seizures perampanel
azathioprine based on endoscopy after clinical remission in moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the aim of this study is to determine whether azathioprine is effective for mucosal healing in uc patients who achieved clinical remission by the first course of corticosteroids but not mucosal healing in endoscopy.

the sample size was calculated based on the previous study showing the difference of mucosal healing rate between azathioprine (58%) and 5-aminosalicylate (21%). with a two-tailed test of α = 0.05 and 1 - ß = 0.8, 52 patients were required. the placebo drug which is identical to azathioprine will be provided by celltrion drug company. differences in the categorical variables between the groups are examined with χ2 or the fisher exact test. for comparisons of continuous variables, a student t test is used.

Eligibility criteria:
inclusion criteria: * ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids * newly diagnosed or without steroid use during last 1 year * endoscopic mayo subscore \>0 exclusion criteria: * patients with azathioprine or biologics therapy
prevalence of bruxism in a group of preschool egyptian children

Conditions: Bruxism

Summary: the protocol is to show the prevalence of bruxism among a group of egyptian children

many studies are done on children to show the prevalence of bruxism among different ages , reports of prevalence range from 8-31% in the general population, the prevalence of bruxism in egyptian children is unknown. several symptoms are commonly associated with bruxism, including hypersensitive teeth, aching jaw muscles, headaches, tooth wear, damage to dental restorations (e.g. crowns and fillings) and damage to teeth. however it may cause minimal symptoms, and therefore people may not be aware of the condition,so this study is important to determine the prevalence of bruxism of preschool egyptian children

Eligibility criteria:
inclusion criteria: 1. cooperative children from 3-6 years 2. children without any medical problems 3. children of families who accept to participate in the study exclusion criteria: 1- children with caries in posterior teeth
functional recovery in stroke patients with task-specific robot-aided arm therapy

Conditions: Stroke; Upper Extremity Paresis

Summary: the goal of this study is to determine whether task-oriented, robot-aided therapy is more effective than conventional physical and occupational therapy at promoting functional recovery of the affected arm in chronic hemiparetic stroke patients.

robotic therapy will be performed with armin, which is a robotic arm exoskeleton that permits 3d movements of both proximal and distal arm joints. combined with an audiovisual display, this device allows virtual training of activities of daily living (adl) and therapeutic gaming. a patient-responsive controller enables the assistance of the device only as needed. chronic stroke patients (\>6 months post stroke) will be randomly assigned to either an experimental or a control group. the experimental group will perform task-related intensive therapy with the support of armin. therapists will treat the patients of the control group with standard motor relearning therapy.

Eligibility criteria:
inclusion criteria: * age 18 or more * first-ever stroke (hemorrhagic or ischemic), verified by brain imaging * stroke more than six months prior to the study * termination of conventional therapy and stable recovery stage (outpatients) * moderate to severe motor impairment of the arm (upper limb portion of fma score between 8 and 38) * ability to sit in a chair without any additional support and without leaning on the back rest * written informed consent signed by the subject (or an authorized representative) exclusion criteria: * excessive spasticity of the affected arm (mas ≥ 3) * any serious medical or psychiatric illness * participation in any clinical investigation within 4 weeks prior to the start of this study * anticipated need for any major surgery during the study * women known to be pregnant or lactating * orthopedic, rheumatologic or other disease restricting movements of the paralyzed upper extremity * shoulder subluxation (palpatory \> 2 fingers) * diseased or damaged skin at the paralyzed arm * inability to communicate effectively with the neurological examiner such that the validity of the patient's data could be compromised * cyber sickness * pace-maker or other implanted electric devices * body weight \> 120kg * serious cognitive deficits and aphasia preventing the performance of the armin treatment * participation in any therapeutic treatment ("outside therapy") performed with the paralyzed arm during the planned study - including baseline and follow up.

Keywords: stroke chronic rehabilitation robot therapy arm therapy